Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Gufic Biosciences Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended December 31, 2016
Gufic Biosciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here Updates
Gufic Biosciences Ltd has submitted to BSE a copy of notice published in the newspapers on December 15, 2016 as required under IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, inviting attention of concerned shareholders to lodge their claims in respect of unclaimed dividends of the Company for last seven years, failing which their shares would be transferred to Investor Education and Protection Fund ('IEPF') Suspense account,... Updates on Outcome of Board Meeting - Resignation of Director
Gufic Biosciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 14, 2016, inter alia, has accepted the resignation of Mr. Ashok M. Tarale as an Independent Director of the Company w.e.f. November 14, 2016. Appointment of Additional Independent Director
Gufic Biosciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 24, 2016, inter alia, has appointed Mr. Gopal Daptari as an Additional Independent Director of the Company with immediate effect upto the conclusion of the ensuing Annual General Meeting. Outcome of Board Meeting
Gufic Biosciences Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 24, 2016, inter alia, has approved the Scheme of Amalgamation of M/s. Gufic Stridden Bio-Pharma Private Limited with the Company, subject to the necessary approvals. Standalone Financial Results, Limited Review Report for September 30, 2016
Gufic Biosciences Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Standalone Limited Review for the period ended September 30, 2016 Board Meeting Intimation for Results & Closure of Trading Window
Gufic Biosciences Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on November 14, 2016, inter alia, to consider and approve the Unaudited Financial Results of the Company for the half year and quarter ended September 30, 2016.Further, pursuant to the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 and as per the terms of "Code of Conduct... Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Gufic Biosciences Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Gufic Biosciences Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here